Post Profile






Study results offer another boon for PARP inhibitors in treatment of advanced breast cancer

SAN ANTONIO - Patients with certain advanced hereditary breast cancers may have new treatments options on the horizon, according to two studies presented this week at the annual San Antonio Breast Cancer Symposium. Susan Domchek, MD, executive director of the Basser Center for BRCA at Penn's Abramson Cancer Center, will present new results from the Mediola and OlympiAD trials showing continued success of treating BRCA-related metastatic breast cancer with the PARP inhibitor olaparib with limited side effects for patients.
read more

share

Related Posts


Study Points to Possible New Treatment for HER2+ Breast Cancer

Health : Newswise Medical News

Elevated PARP1 polymerase in HER2+ breast cancer may confer susceptibility to PARP inhibitor drugs. This proof of concept study using breast cancer tissue from 307 cancer patients lays the groundwork for future clinical trials.

'Epigenetic' Drug May Boost Success of PARP Inhibitor Treatment for Certain Leukemias and Breast Cancers

Health : Newswise Medical News

Drugs called PARP inhibitors, which sabotage cancer cells' ability to repair damage to their DNA, have shown some promise in treating human breast cancers that contain BRCA1 and BRCA2 gene mutations. Now, a new study in lab-grown ca...

Certain advanced breast cancer patients may benefit from surgery before other treatment, UPMC-advised study finds

Health : Medical News Today

Patients newly diagnosed with advanced breast cancer and a solitary bone metastasis could benefit from surgery prior to other treatment, according to early results from a first-of-its kind clinical trial presented at the 2013 San An...

Study results offer another boon for PARP inhibitors in treatment of advanced breast cancer

Diseases & Conditions / Cancer : EurekAlert: Cancer

(University of Pennsylvania School of Medicine) Patients with certain advanced hereditary breast cancers may have new treatments options on the horizon, according to two studies presented this week at the annual San Antonio Breast C...

New Mediola and OlympiAD Trial Results Offer Another Boon for PARP Inhibitors in Treatment of Advanced BRCA-Related Breast Cancer

Health : Newswise Medical News

Patients with certain advanced hereditary breast cancers may have new treatments options on the horizon, according to two studies presented this week at the annual San Antonio Breast Cancer Symposium. Susan Domchek, MD, executive di...

Comments


Copyright © 2016 Regator, LLC